Abstract
New areas in biotechnology have progressed remarkably and are expected to produce new industries. Its methods have already been applied to a wide range of fields, such as agriculture, the chemical, food, energy and pharmaceutical industries. The key factors in biotechnology are gene manipulation, cell fusion, large-scale cell culture, and technology for bioreactors; pertinent industrial processes will require highly developed and precise equipment. The actual market scale of biotechnology has enlarged to more than 100 billion yen ($0.7 billion) in 1989 according to Nikkei Biotech (1989). Although an investigation by BIDEC (Bioindustry Development Center in the Japanese Association of Fermentation and Industry) reports that the industrial scale of biotechnology will grow up to 15,000 billion yen ($100 billion) per year by the twenty-first Century, most of the technology is now in the research and development stage. Rapid development is expected.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Borel, J. F., C. Feurer, C. Magnee, and H. Stahelin. 1977. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 32:1017–1025.
Dreyfuss, M., E. Harii, H. Hoffman, H. Kobel, W. Pache, and H. Tscherter. 1976. Cyclosporin A and C. Eur. J. Appl. Microbiol. 3:125–133.
Endo, A. 1979. Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J. Antibiotics 32:852–854.
Endo, A., M. Kuroda, and Y. Tsujita. 1976. ML-236A, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J. Antibiotics 29:1346–1348.
Fukujoji, S., M. Sugihara, H. Imai, T. Soejima, and Y. Odawara. 1987. Trends of biotechnology equipment. Hitachi Hyoron 69:289–294.
Freidinger, R. M. 1989. Cholecystokinin and gastrin antagonists. Medicinal Res. Rev. 9:271–290.
Goetz, M. A., M. Lopez, R. L. Monaghan, R. S. L. Chang, V. J. Lotti, and T. B. Chen. 1985. Asperlicin, a novel nonpeptidal cholecystokinin antagonist from Aspergillus alliaceus. J. Antibiotics 38:1633–1637.
Kino, T., H. Hatanaka, M. Hashimoto, M. Nishiyama, T. Goto, M. Okuhara, M. Kohsaka, H. Aoki, and H. Imanaka. 1987. FK-506, a novel immunosuppressant isolated from a streptomyces. J. Antibiotics 40:1249–1255.
Nikkei Biotech, ed. 1989. Nikkei Biotechnology Yearbook 89/90. Nikkei Biotech Press, Tokyo.
Nukumi, M., F. Iwatani, M. Ohkuma, and Y. Odawara. 1987. Automatic colony transfer and analyzing system. Hitachi Hyoron 69:313–319.
Ohkawa, T., M. Nukumi, S. Nishimura, T. Okuda, T. Furumai, and T. Honda. 1989. Instrument for the Liquid Culture. Japanese Patent Kokai H1–225476 Sept. 8, 1989.
Umezawa, H., T. Aoyagi, H. Suda, M. Hamada, and T. Takeuchi. 1976. Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J. Antibiotics 29:97–99.
Umezawa, H., T. Aoyagi, T. Hazato, K. Uotani, F. Kojima, M. Hamada, and T. Takeuchi. 1978. Esterastin, an inhibitor of esterase, produced by actinomycetes. J. Antibiotics 31:639–641.
Umezawa, H., T. Aoyagi, K. Uotani, M. Hamada, T. Takeuchi, and S. Takahashi. 1980. Ebelactone, an inhibitor of esterase, produced by actinomycetes. J. Antibiotics 33:1594–1596.
Umezawa, H., T. Aoyagi, S. Ohuchi, A. Okuyama, H. Suda, T. Takita, M. Hamada, and T. Takeuchi. 1983. Arphamenine A and B, new inhibitors of amino-peptidase B, produced by bacteria. J. Antibiotics 36:1572–1575.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Van Nostrand Reinhold
About this chapter
Cite this chapter
Okuda, T., Tabuchi, H. (1992). Automated System for Microbial Screening/Breeding. In: Bhatnagar, D., Cleveland, T.E. (eds) Molecular Approaches to Improving Food Quality and Safety. Springer, New York, NY. https://doi.org/10.1007/978-1-4684-8070-2_6
Download citation
DOI: https://doi.org/10.1007/978-1-4684-8070-2_6
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4684-8072-6
Online ISBN: 978-1-4684-8070-2
eBook Packages: Springer Book Archive